Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oklo Inc (OKLO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

OKLO trades at $48.85, down 0.85% on the day, reflecting ongoing volatility as the stock remains 70% below its 52-week high. Technical indicators show a bearish trend with support at $45, while fundamentals reveal significant losses with a net income of -$105.66M in 2025. Recent news highlights progress with DOE safety approvals for its Groves reactor, but investor sentiment is mixed amid substantial cash burn and equity dilution from financing activities.

The outlook hinges on successful reactor deployment and commercialization, with analyst consensus pointing to 96% upside potential. Key risks include execution delays, regulatory hurdles, and persistent negative cash flow from operations. Long-term growth depends on converting nuclear technology advancements into revenue, making it a high-risk, high-reward opportunity for speculative investors.